Global Non-Hodgkin’s Lymphoma Treatment Market Report and Forecast 2024-2032

Global Non-Hodgkin’s Lymphoma Treatment Market Outlook

The global non-Hodgkin’s lymphoma treatment market attained a value of USD 13.44 billion in 2023. The market is expected to grow further at a CAGR of 7.2% during the forecast period of 2024-2032 to attain a value of USD 25.13 billion by 2032, driven by the rising technological advancement and the increased availability of treatments.

Non-Hodgkin’s Lymphoma Treatment Market: Introduction

Non-Hodgkin's lymphoma is the type of cancer that develops in the white blood cells of the immune system, which are also known as lymphocytes. When these white blood cells start growing abnormally, they start forming tumours throughout the body. 

Major sites of these lymph tissue include lymph nodes, spleen, bone marrow, thymus, digestive tract, adenoids, and tonsils, among others. NHL is inclusive of different types of blood cancers. The subtypes can either progress slowly (indolent subtype) or spread rapidly (aggressive subtype). The non-Hodgkin’s lymphoma can be of two types, that is B cells and T cells. B cells are the cells which are responsible for producing antibodies which help in fighting off infections. On the other hand, T cells have different functions, including the role of providing support to the B cells in antibodies production. 

While the exact cause of non-Hodgkin’s lymphoma continues to be ambiguous, some of the potential factors responsible for the condition are genetic factors, lifestyle, infections, weak immune system, occupation, and the medical history of the patient as well as their family, among other factors. 

The symptoms of the condition are sometimes so common that the patient tends to mistake them for general flu or virus. The signs and symptoms significantly rely on factors like the location of the tumour, its size, and its growth speed. The most common signs and symptoms of the disease include fever, nausea, fatigue, significant weight loss, skin problems like rashes or itchy skin, pain in bones, abdomen, or chest without any reason, severe sweat at night, and swollen lymph nodes, among others.

These symptoms can either happen separately or all at once. For instance, when symptoms like night sweats, severe weight loss, and fever happen together, then these symptoms are clubbed as B symptoms.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Non-Hodgkin’s Lymphoma Treatment Market Segmentations

The market can be categorized into segments like treatment type, disease type, diagnosis, and major regions.

Market Breakup by Treatment Type

• Immunotherapy

• Targeted Therapy

• Chemotherapy

• Others

Market Breakup by Disease Type

• B Cell Lymphoma

• T Cell Lymphoma

Market Breakup by Diagnosis

• Biopsy
  • Bone Marrow Aspiration and Biopsy
  • Excisional or Incisional Biopsy
  • Needle Biopsy
• Cell and Tissue Study
  • Fluorescence in situ Hybridization
  • Polymerase Chain reaction
  • Immunophenotyping
• Blood Tests
  • Complete Blood Count
  • Blood Chemical Test
• Imaging Tests
  • Chest X-Ray
  • CT Scan
  • MRI
  • Ultrasound
  • Bone Scan
  • PET Scan
• Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Non-Hodgkin's Lymphoma Treatment Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Non-Hodgkin’s Lymphoma Treatment Market Scenario

The growth of the market is likely to grow significantly over the forecast period owing to the rising number of cases amongst children. The rising demand for the treatment market can also be attributed to the rising technological advancements, rising number of approved drugs and treatments, as well as the development of new and advanced drugs.

Globally, North America is anticipated to account for a significant share over the coming years since the region is technologically advances and the awareness about different types of cancer in the region is high. The awareness about the importance of conducting regular health check-ups has also propelled the growth of the market.  Other than North America, Europe and Asia Pacific are also likely to witness robust growth in the coming years with the rapidly rising number of cases across these regions.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Non-Hodgkin’s Lymphoma Treatment Market- Epidemiology

The prevalence of the disease is constantly across the globe. The total number of cases in the year 2023 reached around 570,000. Older people are more vulnerable to this condition, especially people belonging to the age group of 65-75; however, it can happen to anyone. Men are more likely to suffer from the disease than women. People who consume immunosuppressant drugs immediately after any organ transplant are also at a higher risk of having this condition.

NHL is a disease which attacks people who have a weaker immune system. Variety of factors could lead to a weaker immune system. These factors include inherited immunity ailments like Wiskott-Aldrich syndrome and hypogammaglobulinemia, autoimmune conditions like HIV/ AIDS, psoriasis, arthritis, or Sjögren syndrome, Helicobacter pylori infection, and Epstein-Barr virus infection or Human T-lymphotropic virus type I.

Non-Hodgkin’s Lymphoma Treatment Market- Therapeutic Landscape

Various treatment methods are used for NHL including radiation therapy, chemotherapy, immunotherapy, targeted therapy, Plasmapheresis, antibiotic therapy, and surgery, among others. The three major treatment methods covered in this report include the following:

Immunotherapy- This treatment uses the patient’s immunity system to fight the cancer cells. Medications are used to boost the immunity system of the patient to kill the cancer cells, which also helps in preventing further growth of cancer cells. Immunomodulators like Lenalidomide are used to treat adult non-Hodgkin lymphoma. Immunotherapy also includes the use of CAR T-cell therapy.

Targeted Therapy- This therapy uses certain drugs to attack the cancer cells. Some of the prominent therapies under this treatment type include proteasome inhibitor therapy, monoclonal antibody therapy, and kinase inhibitor therapy.

• Proteasome Inhibitor Therapy: The inhibition of proteasome might help in killing the cancer cells. Drugs like Bortezomib or ixazomib are used in this treatment method.

• Monoclonal Antibody Therapy: It comprises the use of drugs like Rituximab, Mogamulizumab, Brentuximab vedotin, Obinutuzumab, Tafasitamab, Polatuzumab vedotin, Pembrolizumab, and Yttrium Y 90-ibritumomab tiuxetan, among others.

• Kinase Inhibitor Therapy: This therapy helps in inhibiting the growth of protein cells which might be contributing to the growth of cancer cells in the body. It includes the use of drugs like Copanlisib, acalabrutinib, zanubrutinib, and Ibrutinib.

• Other treatments included in targeted therapy are Histone methyltransferase inhibitor therapy and B-cell lymphoma-2 (BCL-2) inhibitor therapy.

Chemotherapy- This treatment includes the use of drug which is given either orally or through drip or injections to the patient. In some cases, the patient might require a combination of both. To avoid the risk of cancer reaching the brain, these injections might be injected directly into the cerebrospinal fluid, that is around the spine. Chemotherapy is given in an interval of months, depending on the patient’s response to the drugs.

No matter which method of treatment is opted for the patient, these drugs are extremely strong and lead to sever side effects. Some of these toxic side effects also include loss of fertility, paralysis, different types of cancer, and baldness, among others.

Key Players in the Global Non-Hodgkin’s Lymphoma Treatment Market

The major companies working on the drugs and treatment of the condition, and investing in the clinical trials include the following:

• Eli Lilly and Company

• Corvus Pharmaceuticals

• Rafael Pharmaceuticals

• AbbVie

• ADC Therapeutics

• Genetech

• Tessa Therapeutics

• Bristol Myers Squibb

Key Highlights of the Report